Affordable Access

Publisher Website

INTERNATIONAL TRIAL OF LONG-TERM DEXFENFLURAMINE IN OBESITY

Authors
Journal
The Lancet
0140-6736
Publisher
Elsevier
Publication Date
Volume
334
Issue
8672
Identifiers
DOI: 10.1016/s0140-6736(89)91499-2

Abstract

Abstract In a randomised, placebo-controlled, double-blind study, 822 obese patients of both sexes were given either dexfenfluramine (dF), 15 mg twice daily (404), or placebo (418) in addition to a calorie-restricted diet for 1 year. Patients in both groups lost weight significantly in the first 6 months; after 6 months dF patients had a higher cumulative mean weight loss. Dropout rates were lower in dF patients than in placebo patients, mainly because of dissatisfaction with weight loss in the latter group. More than twice as many dF patients as placebo patients achieved a given weight loss; but more dF patients than placebo patients had transient side-effects (tiredness, diarrhoea, dry mouth, polyuria, and drowsiness).

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

INDEX (international dexfenfluramine study) as a m...

on International journal of obesi... December 1992

[Tolerance and acceptability of dexfenfluramine in...

on Revue médicale de la Suisse r... January 1997

Dexfenfluramine treatment of obesity: a double bli...

on International journal of obesi... March 1995
More articles like this..